Soft Corticosteroids with Hydrolytically Labile Groups
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current potent glucocorticosteroids used for anti-inflammatory purposes often cause severe systemic side effects due to their ability to be absorbed into the bloodstream, leading to issues like increased intraocular pressure and glaucoma, highlighting a need for potent local anti-inflammatory agents with minimal systemic activity.
Innovation Solution
Development of 'soft' corticosteroids such as etiprednol dicloacetate and its analogs, which are designed to have high local anti-inflammatory activity while minimizing systemic absorption through specific structural modifications like the 17α-dichloroacetyl function, enhancing hydrolytic susceptibility and reducing systemic toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If potent glucocorticosteroids are applied topically or locally, then anti-inflammatory activity is improved, but systemic side effects worsen due to absorption into bloodstream
Solution Approach 1:
The patent modifies the chemical structure of corticosteroids by introducing a 17α-dichloroacetoxy group and other substituents, which changes the pharmacokinetic parameters of the drug. This structural modification increases hydrolytic susceptibility, causing the drug to be rapidly deactivated in the bloodstream, thereby reducing systemic side effects while maintaining potent local anti-inflammatory activity at the application site.
Solution Approach 2:
The patent introduces ester and thioester groups as intermediary structures that facilitate rapid hydrolysis of the active corticosteroid form in the bloodstream. These intermediary groups act as temporary carriers that deliver the active compound to the target site and then quickly convert it to inactive forms, preventing systemic absorption and side effects.
2Reliability
If glucocorticosteroids are applied to the eye, then local anti-inflammatory effect is achieved, but intraocular pressure increases leading to glaucoma
Solution Approach 1:
The patent modifies the corticosteroid structure with 17α-dichloroacetoxy and other groups that increase hydrolytic susceptibility. This parameter change ensures rapid deactivation of the drug in the ocular environment, preventing accumulation and the development of corticosteroid-induced glaucoma while maintaining effective local anti-inflammatory action.
3Reliability
If corticosteroid potency is increased through structural modifications, then anti-inflammatory activity is improved, but systemic absorption and toxicity worsen
Solution Approach 1:
The patent introduces structural modifications including 17α-dichloroacetoxy groups, fluorine substituents at 6α and 9α positions, and methyl groups at 16α position. These modifications enhance receptor binding affinity and local anti-inflammatory potency while the ester/thioester linkages ensure rapid hydrolytic deactivation, creating a disconnect between local efficacy and systemic exposure.
Solution Approach 2:
The patent converts the potential harm of high potency corticosteroids (systemic toxicity) into a benefit by introducing hydrolytically labile groups. The very structural features that enhance potency also make the molecule susceptible to rapid hydrolysis, thereby converting a high-risk compound into a safe, locally-acting drug with minimal systemic exposure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These soft corticosteroids demonstrate improved therapeutic indexes with enhanced local activity and reduced systemic side effects, effectively managing inflammation in various tissues without the severe systemic repercussions of traditional glucocorticosteroids.
Implementation Method 1
enhancing hydrolytic susceptibility
Data Source
AI summary
Potent soft corticosteroid pharmaceutical compositions comprising them and method for use as anti-inflammatory agents. Also, a method for softening fluticasone propionate and similar corticosteroids to arrive at potent but safer alternatives. The compound 5-fluoromethyl 17α-dichloroacetoxy-6α,9α-difluoro-11β-hydroxy-16a-methyl-3-oxoandrosta-1,4-diene-17β-carbothioate, which is equally potent to but safer than fluticasone, is among those provided. Another compound of particular interest is 2-hydroxyethyl 17α-dichloroacetoxy-6α,9α-difluoro-11β-hydroxy-16β-methyl-3-oxoandrosta-1,4-diene-17β-carboxylate.